natgillin/translations-raw huggingface dataset:
Fatal encephalopathy has been reported, however, the majority of neurologic events (74.5 %) were clinically reversible and resolved following interruption of BLINCYTO.
Prijavljena je encefalopatija sa smrtnim ishodom, međutim većina neuroloških događaja (74,5%) bili su klinički reverzibilni i povukli su se nakon privremenog prekida primjene lijeka BLINCYTO.
Fatal events in patients treated with Stivarga were uncommon (0.6%), and involved the respiratory, gastrointestinal and genitourinary tracts.
Smrtni slučajevi u bolesnika liječenih lijekom Stivarga bili su manje česti (0,6%) i zahvaćali su dišni, probavni i mokraćno-spolni sustav.
Fatal events that were considered possibly related to pazopanib included gastrointestinal haemorrhage, pulmonary haemorrhage/haemoptysis, abnormal hepatic function, intestinal perforation and ischemic stroke.
Događaji s fatalnim ishodom za koje se smatralo da bi mogli biti povezani s pazopanibom uključivali su gastrointestinalno krvarenje, plućno krvarenje/hemoptizu, poremećaj funkcije jetre, perforaciju crijeva i ishemični moždani udar.
Fatal gastrointestinal bleeding occurred in 0.98% of patients receiving placebo in the GIST phase 3 study.
Smrtonosno gastrointestinalno krvarenje pojavilo se u 0,98% bolesnika koji su dobivali placebo u ispitivanju GIST-a faze III.
fatal gastrointestinal haemorrhage*
fatalno gastrointestinalno krvarenje
Fatal Guillain- Barré syndrome has been reported in clinical trials.
U kliničkim je ispitivanjima zabilježen Guillain-Barréov sindrom sa smrtnim ishodom.
Fatal haemorragic events have occurred.
Zabilježeni su slučajevi krvarenja sa smrtnim ishodom.
Fatal haemorrhage was reported in per 100 patient years and intracranial haemorrhage in 0.4 per 100 patient years.
Smrtonosno krvarenje prijavljeno je u 0,2 na 100 bolesnik-godina, a intrakranijalno krvarenje u 0,4 na 100 bolesnik-godina.
Fatal haemorrhages have occurred in the cabozantinib clinical program.
U kliničkom programu primjene kabozantiniba bilo je pojave smrtonosnih krvarenja.
Fatal intracranial haemorrhages have occurred for trametinib in combination with dabrafenib in 1% (3/209) of patients in study MEK115306 and in <1% (3/350) of patients in study MEK116513.
Smrtonosna intrakranijalna krvarenja pojavila su se uz trametinib u kombinaciji s dabrafenibom u 1% (3/209) bolesnika u ispitivanju MEK115306 te u < 1% (3/350) bolesnika u ispitivanju MEK116513.
Fatal intracranial haemorrhages have occurred for trametinib in combination with dabrafenib in 1% (3/209) of patients in study MEK115306 and in <1% (3/350) of patients in study MEK116513.
Smrtonosna intrakranijalna krvarenja uz trametinib u kombinaciji s dabrafenibom javila su se u 1% (3/209) bolesnika u ispitivanju MEK115306 te u < 1% (3/350) bolesnika u ispitivanju MEK116513.
Fatal outcome was reported in 0.8% of patients receiving Avastin compared to 0.5% in patients receiving chemotherapy alone.
Smrtni je ishod prijavljen u 0,8% bolesnika koji su primali Avastin te u 0,5% bolesnika koji su primali samo kemoterapiju.
Fatal outcomes have been reported for acute overdoses as low as 450 mg but survival has also been reported following acute overdose of approximately 2 g of oral olanzapine..
Zabilježeni su i smrtni ishodi kod akutnog predoziranja već pri maloj dozi od 450 mg, ali opisano je i preživljavanje nakon akutnog predoziranja od oko 2 g oralnog olanzapina.
Fatal PE or Death where PE cannot be ruled out
PE sa smrtnim ishodom/smrt gdje se PE nije mogla isključiti
Fatal PE/Death where PE
Smrtonosni PE/Smrt za koju se ne može isključiti PE
Fatal PE/Death where PE cannot be ruled out
Smrtonosni PE/smrt gdje se ne može isključiti PE
Fatal PE/Death where PE cannot be ruled out
Smrtonosni PE/smrt gdje se PE nije mogao isključiti
Fatal PE/Death where PE cannot be ruled out
Smrtonosni PE/smrt za koju se ne može isključiti PE
Fatal toxic epidermal necrolysis has been reported in < 1% of patients who received ipilimumab in combination with gp100 (see section 5.1).
Smrtonosna toksična epidermalna nekroliza zabilježena je u < 1% bolesnika koji su primali ipilimumab u kombinaciji s gp100 (vidjeti dio 5.1).
Fatal ventricular fibrillation was reported in 1 patient (0.3%), and cardiac arrest in 2 patients (0.5%).
Smrtonosna ventrikularna fibrilacija prijavljena je u 1 bolesnika (0,3%), a srčani zastoj u 2 bolesnika (0,5%).
Fatalities due to neutropenic colitis have been reported in clinical trials with topotecan.
U kliničkim ispitivanjima topotekan prijavljeni su slučajevi neutropenijskog kolitisa sa smrtnim ishodom.
Fatalities due to neutropenic colitis have been reported in clinical trials with topotecan.
U kliničkim ispitivanjima topotekana prijavljeni su slučajevi neutropenijskog kolitisa sa smrtnim ishodom.
Fatigue
(0,87-1,15)
fatigue
glavobolja
fatigue
mučnina
Fatigue
neuobičajeno
Fatigue
omnolenciju umor
fatigue
Pretrage
Fatigue
primjene
Fatigue
proljev
Fatigue
reakcije na
Fatigue
umor
fatigue
umor edem
fatigue
umor,
fatigue (3.5% vs 4.6%)
umor (3,5% prema 4,6%)
Fatigue (asthenia, fatigue)
umor (astenija, umor)
fatigue (feeling tired)
umor (osjećaj umora)
fatigue (feeling tired) headache
iscrpljenost (osjećaj umora) glavobolja
fatigue (feeling tired) headache
umor (osjećaj umora) glavobolja
Fatigue (G3/4: 3.9%); Fluid retention (severe: 0.6%)
umor (G3/4: 3,9%); retencija tekućine (teška: 0,6%)
fatigue (weariness), pain, fever, headache
umor (klonulost), bol, vrućica, glavobolja
fatigue aggravated, feeling hot, feeling cold, asthenia, chest pain, chest tightness, influenza like illness, injection site rash, malaise
pojačani umor, osjećaj vrućine, osjećaj hladnoće, astenija, bol u prsištu, stezanje u prsištu, bolest nalik gripi, osip na mjestu injiciranja, malaksalost
Fatigue and asthenia
Umor i astenija
Fatigue and asthenia Malaise
Umor i astenija
Fatigue and vertigo
umor i vrtoglavica
Fatigue Asthenia
umor, astenija
fatigue backache
umor bol u leđima
fatigue decreased feeling or sensitivity of the mouth
umor smanjen osjet ili osjetljivost u ustima
Fatigue has been reported in patients taking Esbriet.
U bolesnika koji uzimaju Esbriet prijavljen je umor.
Fatigue has been reported with the use of azacitidine.
Uz primjenu azacitidina zabilježen je umor.
Fatigue including asthenia
Umor uključujući asteniju
Fatigue including asthenia, flushing, feeling hot
Umor uključujući asteniju, crvenilo uz osjećaj vrućine
fatigue increase in appetite
umor povećan apetit
fatigue increase in the level of liver proteins
umor povišene razine jetrenih proteina
Fatigue Influenza-like illness Pyrexia Oedema peripheral
umor, bolest nalik gripi, pireksija, periferni edem
Fatigue Malaise
umor malaksalost
Fatigue Malaise Thirst
umor malaksalost žeđ
Fatigue Pyrexia Chills Irritability Malaise
Umor Pireksija Zimica Razdražljivost Malaksalost
Fatigue Pyrexia Chills Malaise
Umor Pireksija Zimica Malaksalost
Fatigue Pyrexia Irritability
umor, pireksija, razdražljivost
fatigue swelling, particularly in the ankles and eyelids, and weight gain.
umor oticanje, posebno gležnjeva ili vjeđa, i dobivanje na težini.
Fatigue was observed in approximately 25 % and asthenia in 16 % of patients whilst receiving topotecan.
Umor je primjećen u otprilike 25%, a astenija u 16% bolesnika koji su primali topotekan.
Fatigue*
Umor
fatigue,
umor
fatigue,
umor,
Fatigue,
umor, astenija
Fatigue, accidental injury, facial swelling, high blood pressure, diarrhoea, flatulence, inflammation of the mucous membrane of the mouth, increased liver enzymes, swelling, dizziness, sleeplessness, drowsiness, abnormal thinking, runny nose (rhinitis), cough, shortness of breath, dry skin, itching, rash, sweating, visual disturbance including blurred vision, taste disturbance, urinary tract disorder or infection, impotence, discharge and itching in the vagina, bladder pain, inability to empty your bladder.
Umor, slučajna ozljeda, oticanje lica, povišeni krvni tlak, proljev, vjetrovi, upala sluznice usta, povišene vrijednosti jetrenih enzima, oticanje, omaglica, nesanica, pospanost, poremećaj tijeka misli, curenje iz nosa (rinitis), kašalj, nedostatak zraka, suhoća kože, svrbež, osip, znojenje, poremećaj vida uključujući zamućen vid, poremećaj okusa, poremećaj ili infekcija mokraćnog sustava, impotencija, iscjedak iz rodnice i svrbež rodnice, bol u mokraćnom mjehuru, nemogućnost potpunog pražnjenja mokraćnog mjehura.
Fatigue, Asthenia
umor, astenija
Fatigue, asthenia (including muscular weakness), injection (infusion) site pain
Umor, astenija (uključujući mišićnu slabost), bol na mjestu injekcije (infuzije)
Fatigue, asthenia,
rčani šum,
Fatigue, asthenia, oedema peripheral
Umor, astenija, periferni edem
fatigue, asthenia, oedema peripheral, pyrexia, pain
umor, astenija, periferni edem, pireksija, bol
Fatigue, Asthenia, Peripheral oedema, Influenza like illness syndrome (including pyrexia, cough)
umor, astenija, periferni edem, sindrom bolesti
fatigue, chest discomfort, feeling hot, oedema peripheral, pain, asthenia, chest pain, face oedema, hyperthermia
umor, nelagoda u prsištu, osjećaj vrućine, periferni edem, bol, astenija, bol u prsištu, oticanje lica, hipertermija
fatigue, chest pain, chest discomfort
umor, bol u prsištu, osjećaj nelagode u prsištu
Fatigue, dizziness and asthenia have been reported in some patients taking IMBRUVICA and should be considered when assessing a patient’s ability to drive or operate machines.
Umor, omaglica i astenija bili su prijavljeni u nekih bolesnika koji su uzimali lijek IMBRUVICA i moraju se uzeti u obzir pri procjeni bolesnikove sposobnosti da upravlja vozilima ili radi sa strojevima.
Fatigue, dizziness, depression
umor, omaglica, depresija
Fatigue, Feeling hot
Ubrzan rad srca
Fatigue, feeling hot, oedema peripheral, pyrexia
umor, osjećaj vrućine, periferni edem, pireksija
Fatigue, Fever, Vague illness, Flu-like symptoms
umor, vrućica, blaga bolest, simptomi nalik gripi
Fatigue, gait disturbance, asthenia
Umor, poremećaji hoda, astenija
fatigue, high blood pressure.
umor, visok krvni tlak.
Fatigue, Hyperthermia
Umor, hipertermija
fatigue, injection site reaction, pyrexia
umor, reakcija na mjestu primjene injekcije, pireksija
fatigue, irritability
umor, razdražljivost
Fatigue, malaise
umor, malaksalost
Fatigue, malaise peripheral oedema, withdrawal syndrome*
Umor, malaksalost i periferni edem, sindrom ustezanja
Fatigue, malaise peripheral oedema, withdrawal syndrome*
Umor, malaksalost, periferni edem, sindrom ustezanja
Fatigue, mucosal inflammation*, asthenia†.
Umor, upala sluznice*, astenija†.
fatigue, mucosal inflammation, asthenia
umor, upala sluznice, astenija
Fatigue, mucosal inflammation, pyrexia, chest pain, oedema
Umor, upala sluznica, pireksija, bol u prsnom košu, edem
Fatigue, oedema peripheral
Umor, periferni edem
Fatigue, pain
Umor, bol
Fatigue, pain, thirst
umor, bol, žeđ
fatigue, peripheral oedema
neadekvatno izlučivanje antidiuretskog hormona1
fatigue, peripheral oedema
umor, periferni edem
Fatigue, possibly related to bradycardia
Umor, moguće povezan s bradikardijom
fatigue, pyrexia
umor, pireksija
Fatigue, Pyrexia, Asthenia, Chills
umor, pireksija, astenija, zimica
fatigue, pyrexia, lethargy, oedema peripheral, rigors, fall, chest pain, feeling cold, pain, feeling jittery, pain exacerbated
umor, pireksija, letargija, periferni edem, tresavica, pad, bol u prsištu, osjećaj hladnoće, bol, osjećaj nervoze, pogoršanje bola
Fatigue, pyrexia, oedema peripheral, asthenia
umor, pireksija, periferni edem, astenija
Fatigue, rigors, pyrexia, influenza like illness, asthenia, irritability
umor, tresavica, pireksija, bolest nalik gripi, astenija, razdražljivost
Fatigue, rigors, pyrexia, influenza-like illness, asthenia, malaise, irritability
umor, tresavica, pireksija, bolest nalik gripi, astenija, malaksalost, iritabilnost
Fatigue, rigors, pyrexia, influenza-like illness, asthenia, malaise, irritability
umor, tresavica, pireksija, bolest nalik gripi, astenija, malaksalost, razdražljivost
Fatigue, tiredness
umor, zamaranje
fatigue, weakness abnormal liver function tests
umor, slabost abnormalni rezultati testova jetrene funkcije
Fatigue, weakness, headache, dizziness
Umor, slabost, glavobolja, omaglica
fatigue, weakness, injection site reactions abnormal liver function tests.
umor, slabost, reakcije na mjestu injekcije abnormalni rezultati testova jetrene funkcije
Fatigue, weakness, pain
bol u ustima
Fatigue, weakness, pain
umor, slabost, bol
Fatigue.
Umor.
Fatigue.
zamor.
Fatigue. asthenia
umor, astenija
Fatigue/Asthenia
umor/astenija
Fatigue/Asthenia (53.2%) (G3/4 : 7.7%)
Umor/astenija (53,2%) (G3/4: 7,7%)
Fatigue/feeling tired
izmorenost/osjećaj umora
fatigue1, 2
umor1,2
Fatigue2 Uncommon
Umor2 Manje često
Fatiguea
mjestu primjene
Fatiguea
umora
Fatigueam
Umoram
FatigueD, oedema peripheralD
umorD, periferni edemD
Fatiguej
Umorj
Fatiguel
Umorl
fatty deposits in the liver, enlarged liver;
masne nakupine u jetri, povećana jetra;
fatty liver
masna jetra
fatty liver,
masna jetra
fatty liver;
masna jetra,
Fatty lumps on the surface of the skin (lipohypertrophy), loose skin (cutis laxa), stretched skin, skin discolouration including a lighter area of the skin (skin hypopigmentation)
masne kvrge na površini kože (lipohipertrofija), mlohava koža (cutis laxa), rastegnuta koža, promjena boje kože uključujući područja na koži svjetlije boje (hipopigmentacija kože)
Fatty oily stool Oily evacuation Flatulence
Uljni iscjedak iz crijeva Flatulencija
Fatty or oily stools
Masne ili uljaste stolice
Fatty or oily stools.
Masne ili uljaste stolice
Faulty dosing of methotrexate may lead to serious adverse effects including fatal course.
Neispravno doziranje metotreksata može dovesti do ozbiljnih nuspojava uključujući smrtni ishod.
Favourable risk
Povoljan rizik
Fax +1 614 822 2409
Faks +1 614 822 2409
Fax +34 972 430661
Fax. +34 972 430661
Fax +353 61 585151 medicalinfo@olympusbiotech.com
Faks +353-61-585151 medicalinfo@olympusbiotech.com
fax +44 1753 437 192 e-mail info@amicusrx.co.uk
Faks +44 1753 437 192 e-pošta: info@amicusrx.co.uk
fax : + 33 4 92 08 73 48 e-mail : darprocedure@virbac.com
fax: + 33 4 92 08 73 48 e-mail: darprocedure@virbac.com
Fax number: 02830260201
Broj telefaksa: 02830260201
Fax. +32 (2) 411 28 28
Fax: +32 (2) 411 28 28
Fax: + 34 986 33 65 77 czv@czveterinaria.com
Faks: + 34 986 33 65 77 czv@czveterinaria.com
Fax: + 49 8024 908-1290 ail: service@hexal.com
Fax: + 49 8024 908-1290
Fax: + 49 8024 908-1290 e-mail: service@hexal.com
Fax: +49 8024 908-1290 e-mail: service@hexal.com
Fax: +30 210 6775695
E-28830 San Fernando de Henares (Madrid)
fax: +31 (0)348 565454 e-mail: info@levetpharma.com
faks: +31 (0)348 565454 e-mail: info@levetpharma.com
fax: +31 (0)348565454 e-mail: Info@levetpharma.com
faks: +31 (0)348565454 e-mail: Info@levetpharma.com
fax: +31 (0)348565454 e-mail:Info@levetpharma.com
faks: +31 (0)348565454 e-mail: Info@levetpharma.com
fax: +351 22 986 61 90 e-mail: info@bial.com
faks: +351 22 986 61 90 e-mail: info@bial.com
Fax: +39 031 5373241 info@gentium.it
Faks: +39 031 5373241 info@gentium.it
Fax: +44 (0) 19 39 21 12 01
Faks: +44 (0) 19 39 21 12 01
Fax: +44 (0) 20 7887 6001
Faks: +44 (0)20 7887 6001
Fax: +44 (0) 20 7887 6001 eMail: regulatory@omeros.co.uk
Faks: +44 (0)20 7887 6001
Fax: +44 (0)1372 461401
Fax: +44 (0) 1372 461401
Fax: +44 (0)1932 571110
Telefaks: +44 (0)1932 571110
Fax: +44 (0)1932 573800
Telefaks: +44 (0)1932 573800
Fax: +44 (0)20 7566 4010
Faks: +44 (0)20 7566 4010
fax: +44 (0)208 600 1401 e-mail: EUmedinfo@eisai.net
faks: +44 (0)208 600 1401 e-mail: EUmedinfo@eisai.net
Fax: +49 (0) 752 57 00 5
Faks: +49 (0) 752 57 00 5
Fax: +49 (0)7121 346 255 e-mail: info@biopartners.de
Fax: +49 (0)7121 346 255
Fax: 0039.0836.1975111 or 0039.0733.560376
Fax: 0039.0836.1975111 ili 0039.0733.560376
Fax: 0049 (0)30 744 60 41
Faks: 0049 (0)30 744 60 41
FBCs including platelet counts and peripheral blood smears should be obtained monthly thereafter.
Nakon toga KKS i broj trombocita te razmaz periferne krvi treba kontrolirati jednom mjesečno.
FC II patients
Bolesnici funkcionalnog razreda II
FC subgroups are based on the select patient populations in DUET-1 and DUET-2 and are not meant to represent definitive clinical susceptibility breakpoints for INTELENCE.
Podskupine FC temelje se na izabranim populacijama bolesnika u ispitivanjima DUET-1 i DUET-2 i ne smatra se da predstavljaju konačne prijelomne točke kliničke osjetljivosti za INTELENCE.
FCF (E110).
Yellow FCF (E110).
FCV (431 and G1 strains) ...............................................................................................  2.0 ELISA U.
FCV (soj 431 i G1) .......................................................................................................  2,0 ELISA U.
FCV (431 and G1 strains) ...............................................................................................  2.0 ELISA U.
FCV (soj 431 i G1)..........................................................................................................  2,0 ELISA U.
Fe rtility, pre gnancy and lactation
Plodnost, trudnoća i doje nje
Fe rtility, pregnancy and lactation
Plodnost, trudnoća i doje nje
Features of randomized patients
Osobine randomiziranih bolesnika
Features of this pen
Tijelo brizgalice
Feb  Jun  Oct
Da  Ne
Feb-2018
veljače 2018.
Febrile
febrilna
Febrile convulsion Hypoaesthesia
Febrilne konvulzije Hipoestezija
febrile disorders, pain and discomfort, asthenic conditions, oedema, body temperature perception disturbed
febrilni poremećaji, bol i nelagoda, astenijska stanja, edemi, poremećen doživljaj tjelesne temperature
febrile neutropaenia
febrilna neutropenija
Febrile neutropaenia (temperature ≥ 38.5°C and absolute neutrophil count < 1,000/µL)
febrilna neutropenija (temperatura ≥ 38,5°C i apsolutni broj neutrofila < 1000/µl)
febrile neutropaenia*
febrilna neutropenija
Febrile neutropaenia, lymphopaenia
febrilna neutropenija, limfopenija
Febrile neutropenia
neutropenijska vrućica
Febrile neutropenia (4.5%) (G3/4: 4.4%)a
Neutropenija (53,6%) (G3/4: 46,0%)
Febrile Neutropenia (ANC  1,000/mm3 and fever  38,5 °C)
Febrilna neutropenija (ABN  1000/mm³ i vrućica  38,5°C)
Febrile neutropenia (decrease in the number of white blood cells accompanied by fever)
Febrilna neutropenija (smanjenje broja bijelih krvnih stanica praćeno vrućicom)
Febrile neutropenia (fever associated with reduction of the number of white blood cells)
Febrilna neutropenija (vrućica povezana sa smanjenjem broja bijelih krvnih stanica)
Febrile neutropenia (FN) was experienced in 6.7% of patients who received Pom + LD-Dex, and in no patients who received HD-Dex.
Febrilnu neutropeniju (FN) razvilo je 6,7% bolesnika koji su primali Pom + LD-Dex i nijedan bolesnik koji je primao visoke doze deksametazona.
Febrile neutropenia (Low white blood cells with fever)
Neutropenijska vrućica (nizak broj bijelih krvnih stanica praćen vrućicom)
Febrile neutropenia and neutropenic infection occurred respectively in 12.1% and 3.4% of patients when patients received prophylactic G-CSF, in 15.6% and 12.9% of patients without prophylactic G-CSF, (see section 4.2).
Febrilna neutropenija i neutropenijska infekcija javile su se u 12,1% odnosno 3,4% bolesnika koji su profilaktički primali G-CSF i u 15,6% i 12,9% bolesnika koji nisu profilaktički primali G-CSF (vidjeti dio 4.2).
Febrile neutropenia and sepsis (common, may affect 1 to 10 patients out of 100):
Febrilna neutropenija i sepsa (često, može se javiti u 1 do 10 od 100 bolesnika):
Febrile neutropenia defined as ANC < 1,000/mm3and fever
Febrilna neutropenija definirana kao ABN < 1000/mm³ i vrućica
Febrile neutropenia Leukopenia
Febrilna neutropenija Leukopenija
Febrile neutropenia Lymphopenia Monocytosis
Febrilna neutropenija Limfopenija Monocitoza
Febrile neutropenia or neutropenic infection
Febrilna neutropenija ili neutropenijska infekcija
Febrile neutropenia Thrombocytopenia (2)
neutropenijska vrućica trombocitopenija (2)
Febrile neutropenia*
febrilna neutropenija
Febrile neutropenia* Neutropenia Leucopenia Anaemia
febrilna neutropenija* neutropenija leukopenija anemija
Febrile neutropenia, anaemia
febrilna neutropenija, anemija
Febrile neutropenia, blood disorder
Febrilna neutropenija, poremećaj krvi
Febrile neutropenia, lymphopenia
febrilna neutropenija, limfopenija
febrile neutropenia, neutropenia (see gastrointestinal disorders), thrombocytopenia, anaemia, leucopenia
febrilna neutropenija, neutropenija (vidjeti poremećaje probavnog sustava), trombocitopenija, anemija, leukopenija
Febrile neutropenia, Pancytopenia, Granulocytopenia, Thrombocytopenia, Leukopenia, Haemolytic anaemia, International Normalised Ratio (INR) increased/Prothrombin time prolonged
febrilna neutropenija, pancitopenija, granulocitopenija, trombocitopenija, leukopenija, hemolitička anemija, povišen INR/produljeno protrombinsko vrijeme
Febrile neutropenia, thrombo- cytopenia, anaemia, leukopenia
Febrilna neutropenija, trombocitopenija, anemija, leukopenija
Febrile neutropenia, thrombocyto- penia, anaemia, leukopenia
Febrilna neutropenija, trombocitopenija, anemija, leukopenija
Febrile neutropenia, thrombocytopenia, anaemia, leukopenia
febrilna neutropenija, trombocitopenija, anemija, leukopenija
Febrile neutropenia, thrombocytopenia, leukopenia
febrilna neutropenija, trombocitopenija, leukopenija
Febrile neutropenia,leukopenia, anaemia, thrombocytopenia and neutropenia occurred very commonly.
Febrilna neutropenija, leukopenija, anemija, trombocitopenija i neutropenija su vrlo česte.
Febrile seizure*, Somnolence
febrilne konvulzije*, pospanost
February 01, 2012 data cut-off date (z)
Podaci do zaključno 1. veljače 2012. (z)
February 1,
1. veljače 2012.
February 2016
Veljača 2016
Febuxostat has been shown to potently inhibit both the oxidized and reduced forms of XO.
Dokazano je da febuksostat snažno inhibira kako oksidirane tako i reducirane oblike XO.
Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO.
Febuksostat je derivat 2-ariltiazola koji postiže terapijski učinak smanjivanjem razine mokraćne kiseline u serumu selektivnim inhibiranjem XO.
Febuxostat is a potent, non-purine selective inhibitor of XO (NP-SIXO) with an in vitro inhibition Ki value less than one nanomolar.
Febuksostat je snažan, nepurinski selektivni inhibitor XO (NP-SIXO) čija je in vitro vrijednost Ki manja od jednog nanomola.
Febuxostat treatment should be immediately stopped if serious allergic/hypersensitivity reactions, including Stevens-Johnson Syndrome, occur since early withdrawal is associated with a better prognosis.
Liječenje febuksostatom treba odmah prekinuti ukoliko se pojave ozbiljne alergijske reakcije/reakcije preosjetljivosti, uključujući Stevens- Johnsonov sindrom, jer je raniji prekid liječenja povezan s boljom prognozom.
Febuxostat use is not recommended in patients concomitantly treated with mercaptopurine/azathioprine.
Ne preporučuje se primjena febuksostata kod bolesnika istodobno liječenih merkaptopurinom / azatioprinom.
Febuxostat use is not recommended in patients concomitantly treated with mercaptopurine/azathioprine.
Ne preporučuje se primjena febuksostata kod bolesnika istodobno liječenih merkaptopurinom/ azatioprinom.
FEC: 5-fluorouracil, epirubicin, cyclophosphamide; TCH: docetaxel, carboplatin and trastuzumab, CMH: Cochran–Mantel–Haenszel
FEC: 5-fluorouracil, epirubicin, ciklofosfamid; TCH: docetaksel, karboplatin i trastuzumab, CMH: Cochran– Mantel–Haenszel
Fed state
Nakon obroka
Feed to which Econor oral powder has been added should be replaced if not consumed within 24 hours.
Hranu u koju je dodan oralni prašak Enocor treba zamijeniti unutar 24 sata ako se ne pojede.
Feed to which the Econor oral powder has been added should be replaced if not consumed within 24 hours.
Hranu u koju je dodan oralni prašak Enocor treba zamijeniti unutar 24 sata ako se ne pojede.
Feed your child regularly to avoid prolonged fast.
Dijete hranite redovito kako biste izbjegli produljena razdoblja gladovanja.
Feeding and giving the dog treats within 15 minutes after administration of the gel should therefore be avoided.
Stoga je 15 minuta nakon primjene gela potrebno izbjegavati hranjenje psa i davanje poslastica.